Endo International (NASDAQ:ENDP) (TSE:ENL) will release its earnings data before the market opens on Thursday, November 8th. Analysts expect Endo International to post earnings of $0.59 per share for the quarter.
Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings results on Wednesday, August 8th. The company reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.54 by $0.22. Endo International had a positive return on equity of 237.45% and a negative net margin of 34.72%. The company had revenue of $714.70 million during the quarter, compared to analysts’ expectations of $679.72 million. During the same quarter in the previous year, the firm earned $0.93 EPS. Endo International’s revenue was down 18.4% on a year-over-year basis. On average, analysts expect Endo International to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Endo International stock opened at $17.14 on Wednesday. Endo International has a 52 week low of $5.27 and a 52 week high of $18.50. The firm has a market cap of $3.85 billion, a PE ratio of 4.46, a price-to-earnings-growth ratio of 1.65 and a beta of 0.65.
In other Endo International news, Director Roger H. Kimmel sold 26,074 shares of the company’s stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $15.90, for a total value of $414,576.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.80% of the company’s stock.
A number of equities analysts have issued reports on the company. Cantor Fitzgerald upped their target price on Endo International from $12.00 to $18.00 and gave the stock a “neutral” rating in a report on Friday, October 19th. BidaskClub raised Endo International from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 2nd. Zacks Investment Research raised Endo International from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a report on Monday, September 24th. Goldman Sachs Group raised Endo International from a “sell” rating to a “neutral” rating and upped their target price for the stock from $14.00 to $15.00 in a report on Tuesday, September 11th. Finally, ValuEngine cut Endo International from a “buy” rating to a “hold” rating in a report on Tuesday, September 4th. Fifteen investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $14.91.
ILLEGAL ACTIVITY WARNING: “Endo International (ENDP) Scheduled to Post Earnings on Thursday” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/11/07/endo-international-endp-scheduled-to-post-earnings-on-thursday.html.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Featured Article: Bond
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.